# AZN — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-07-16. Informational only, not financial advice.

**Recommendation:** ACCUMULATE

**Scores (0–100):** Overall 6.8 · Fundamentals 7.8 · Technicals 3.5 · Growth 7.5 · Risk 6

## Summary

AstraZeneca has sold off ~17% in the past quarter to $168, driven by the Wainua/eplontersen amyloidosis trial setback, dragging the stock below all key moving averages into oversold territory (RSI 38) ahead of the July 27 earnings print. Fundamentals remain solid — 10% TTM sales growth, 28% operating margins, 23% ROE, and a fresh $1.5B Zegfrovy lung-cancer in-licensing deal from Dizal — but the near-term setup is a binary earnings event against a weak tape. I lean constructive at these levels but wait for the print; a pre-earnings starter with room to add below is the right posture.

## Price targets (6-month horizon)

- Bear: $150.00
- Base: $188.00
- Bull: $215.00

## News context

The dominant signal is mixed: the Wainua/eplontersen ATTR-CM Phase 3 setback (partnered with Ionis) is the proximate cause of the selloff and a real hit to a near-term diversification bet. Offsetting that, AZN announced the Dizal Zegfrovy licensing deal ($600M upfront, up to $1.5B) which adds a commercialized EGFR exon 20 NSCLC asset — a fast, tangible revenue lever for the oncology franchise. Seeking Alpha coverage frames the setup as Q2 preview with Enhertu momentum and EU approval as offsets, and a DCF-based note argues the stock may trade at a ~46% discount to intrinsic value post-selloff.

Signal: oncology engine remains intact and is being reinforced; the setback is in a peripheral franchise. Noise: social sentiment is thin (only 4 tagged messages) and dominated by unrelated pumps. Analyst target of $216.99 (+29%) and Recom 1.63 (buy-side) are still constructive, but the July 27 earnings print is the near-term arbiter.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/azn-ai-stock-forecast-0b8d480fc9c521ab4fce62fe36b25a53
- AI-generated; model outputs can be wrong. Not financial advice.